
Novo Nordisk (NVO) Stock Forecast & Price Target
Novo Nordisk (NVO) Analyst Ratings
Bulls say
Novo Nordisk commands a significant presence in the global branded diabetes treatment market, holding approximately one third of the market share. The company is poised for growth, particularly in its GLP-1 franchise, which is projected to experience 25% higher growth, bolstered by anticipated regulatory approvals and a positive Phase 3 trial outcome for semaglutide. Furthermore, improvements in operating expense leverage throughout 2024 are expected to enhance the company's valuation metrics, establishing a favorable outlook for financial performance going forward.
Bears say
Novo Nordisk's growth outlook has been downgraded, with anticipated sales growth in DKK expected to be one percentage point lower than previously anticipated, and operating profit projections reduced by two percentage points. Furthermore, negative outcomes for semaglutide and disappointing Phase 3 data for CagriSema have led to a significant reduction in revenue estimates for these products, as well as a potential decrease in the company's forward P/E multiple to 22x. Compounding these challenges are industry-wide pricing pressures and the risk of unmet revenue expectations, alongside concerns over the stability of key patents that could impact the company's competitive position in the diabetes treatment market.
This aggregate rating is based on analysts' research of Novo Nordisk and is not a guaranteed prediction by Public.com or investment advice.
Novo Nordisk (NVO) Analyst Forecast & Price Prediction
Start investing in Novo Nordisk (NVO)
Order type
Buy in
Order amount
Est. shares
0 shares